W
William J. Murphy
Researcher at Texas A&M University
Publications - 320
Citations - 27304
William J. Murphy is an academic researcher from Texas A&M University. The author has contributed to research in topics: Genome & Immune system. The author has an hindex of 80, co-authored 293 publications receiving 25360 citations. Previous affiliations of William J. Murphy include Pontifícia Universidade Católica do Rio Grande do Sul & Texas College.
Papers
More filters
Book ChapterDOI
Construction of radiation hybrid panels.
John E. Page,William J. Murphy +1 more
TL;DR: A protocol for constructing RH panels by rescuing irradiated fibroblast donor cells of any mammalian species by polyethylene glycol fusion to a thymidine kinase-deficient hamster cell line is described.
Journal ArticleDOI
Response to Comment on “Impacts of the Cretaceous Terrestrial Revolution and KPg Extinction on Mammal Diversification”
William J. Murphy,Jan E. Janecka,Tanja Stadler,Eduardo Eizirik,Oliver A. Ryder,John Gatesy,Robert W. Meredith,Mark S. Springer +7 more
TL;DR: It is shown that the divergence times are ~11 million years later for placental inter- and intraordinal divergences—consistent with a post–Cretaceous-Paleogene radiation of most modern mammalian orders—and find no support for the early Eocene delayed-rise hypothesis.
Journal ArticleDOI
Alternative strategies other than growth hormone for the treatment of immune diseases
William J. Murphy,Dan L. Longo +1 more
Chronic graft-versus-host disease (cGVHD) is a life-threatening impediment to allogeneic hematopoietic stem cell transplantation, and current therapies do not completely prevent and/or treat cGVHD. CD4
Jason A. Dubovsky,Ryan Flynn,Jing Du,Bonnie K. Harrington,Yiming Zhong,Benjamin H. Kaffenberger,Carrie Yang,William H. Towns,Amy Lehman,Amy J. Johnson,Natarajan Muthusamy,Steven M. Devine,Samantha Jaglowski,Jonathan S. Serody,William J. Murphy,David H. Munn,Leo Luznik,Geoffrey R. Hill,Henry K. Wong,Ivan Maillard,John Koreth,Laurence Elias,Corey Cutler,Robert J. Soiffer,Joseph H. Antin,Jerome Ritz,Angela Panoskaltsis-Mortari,John C. Byrd,Bruce R. Blazar +28 more
TL;DR: It is demonstrated that B cells and T cells drive cGVHD and suggest that ibrutinib has potential as a therapeutic agent, warranting consideration for cGV HD clinical trials.